Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -57.77% is 38% below its 2-year average of -41.82%, near the low end of its 2-year range (-57.77%–-25.90%).
As of the fiscal period ended Wednesday, December 31, 2025. 16.04% below its 12-month average of -49.78%.
Annual fiscal-year return on equity; no daily interpolation. Historical series through 2025-12-31.
RETURN ON EQUITY (ROE)
-57.77%
RETURN ON EQUITY (ROE) AVG TTM
-49.78%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-16.04%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-37.51%
vs the sector median at left
First Tracks Biotherapeutics Inc
Market Cap
$1.11B
Return on Equity (ROE)
-57.77%
TTM Avg
-49.78%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.11B
Return on Equity (ROE)
-281.14%
TTM Avg
-124.20%
3Y Avg
-84.35%
5Y Avg
-63.72%
Market Cap
$1.11B
Return on Equity (ROE)
-48.56%
TTM Avg
-84.22%
3Y Avg
-65.23%
5Y Avg
-44.45%
Market Cap
$1.10B
Return on Equity (ROE)
1.05%
TTM Avg
-23.37%
3Y Avg
-7.64%
5Y Avg
-0.10%
Market Cap
$1.13B
Return on Equity (ROE)
N/A
TTM Avg
35.70%
3Y Avg
35.70%
5Y Avg
35.70%
Market Cap
$1.09B
Return on Equity (ROE)
-39.54%
TTM Avg
-24.09%
3Y Avg
36.77%
5Y Avg
36.77%
Market Cap
$1.09B
Return on Equity (ROE)
-6.16%
TTM Avg
-10.85%
3Y Avg
-14.08%
5Y Avg
-9.38%
Market Cap
$1.13B
Return on Equity (ROE)
-244.91%
TTM Avg
-17.45%
3Y Avg
-30.16%
5Y Avg
-48.76%
Market Cap
$1.14B
Return on Equity (ROE)
10.23%
TTM Avg
17.11%
3Y Avg
18.25%
5Y Avg
14.55%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| First Tracks Biotherapeutics Inc (TRAX) | $1.11B | -57.77% | -49.78% | N/A | N/A |
| Replimune Group, Inc. (REPL)vs › | $1.11B | -281.14% | -124.20% | -84.35% | -63.72% |
| Tandem Diabetes Care, Inc. (TNDM)vs › | $1.11B | -48.56% | -84.22% | -65.23% | -44.45% |
| STAAR Surgical Company (STAA)vs › | $1.10B | 1.05% | -23.37% | -7.64% | -0.10% |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.13B | N/A | 35.70% | 35.70% | 35.70% |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.09B | -39.54% | -24.09% | 36.77% | 36.77% |
| OPKO Health, Inc. (OPK)vs › | $1.09B | -6.16% | -10.85% | -14.08% | -9.38% |
| Harrow Health, Inc. (HROW)vs › | $1.13B | -244.91% | -17.45% | -30.16% | -48.76% |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.14B | 10.23% | 17.11% | 18.25% | 14.55% |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.14B | 2.51% | 3.60% | 0.50% | -7.05% |
ROE
-57.8%
ROA
-50.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | -57.77% |
| 2024-12-31 | -41.80% |
| 2023-12-31 | -25.90% |
